GlaxoSmithKline Plc is to contribute adjuvant to an international project to create a vaccine against infections from the coronavirus which originated in China and is rapidly spreading elsewhere. The World Health Organization has declared the spread of the virus to be a public health emergency. GSK will be working with the Coalition for Epidemic Preparedness Innovations (CEPI), a group set up in 2017 to develop vaccines to stop future epidemics.
